Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
REDWOOD CITY, Calif., April 03, 2018 -- ARMO BioSciences, Inc. (Nasdaq:ARMO), a late-stage immuno-oncology company, today announced that Martin Oft, M.D., Senior Vice President, Translational Medicine and Co-Founder, will participate in a panel presentation at the 8th Annual Cancer Immunotherapy Conference, taking place April 4-5 in New York City.
| Presentation Details: | ||||||||||||
| Date: | Wednesday, April 4 | |||||||||||
| Time: | 11:35am Eastern Time | |||||||||||
| Location: | Apella Event Space Alexandria Center, New York City | |||||||||||
| Topic: | Cytokines | |||||||||||
| Panelists: | Martin Oft, M.D., Senior Vice President, Translational Medicine and Co-Founder | |||||||||||
| ARMO BioSciences, Inc. | ||||||||||||
| Deborah Charych, Ph.D., Executive Director of Research & Development | ||||||||||||
| Nektar Therapeutics | ||||||||||||
About the 8th Annual Cancer Immunotherapy Conference
Hosted by William Blair and MaidStone Life Sciences, the annual cancer immunotherapy conference is a unique, two-day conference that brings together the founding scientists, leading clinicians, and pioneering biopharmaceutical companies driving the field of cancer immunotherapy. The agenda is designed to facilitate the exchange of information and highlight potential areas of opportunity for executives, investors, and others involved in transforming the future of cancer treatments. Each day will consist of a series of presentations from leading experts across the various disciplines in immuno-oncology followed by panel discussions to further elucidate key issues and paths forward.
About ARMO BioSciences
ARMO BioSciences is a late-stage immuno-oncology company that is developing a pipeline of novel, proprietary product candidates that activate the immune system of cancer patients to recognize and eradicate tumors. The Company’s lead product candidate, AM0010 (pegilodecakin, PEGylated Interleukin-10), has demonstrated clinical benefit as a single agent, and in combination with both chemotherapy and checkpoint inhibitor therapy, across several tumor types. The drug is currently being investigated in a Phase 3 randomized pivotal clinical trial in pancreatic cancer patients. ARMO also has a number of other immuno-oncology product candidates in various stages of pre-clinical development including: AM0001, an anti-PD-1 monoclonal antibody; AM0003, an anti-LAG-3 checkpoint inhibitor; AM0015, form of recombinant human Interleukin-15 (IL-15); and AM0012, a form of recombinant human Interleukin-12 (IL-12). For more information, please visit www.armobio.com.
CONTACTS:
ARMO BioSciences, Inc.
Herb Cross, Chief Financial Officer
650-241-3993
[email protected]
Dan Ferry
LifeSci Advisors, LLC
617-535-7746
